WEBULL
News
MENS
29.01
-0.62%
-0.18
Jyong Biotech signs MOU with Vietnam pharmaceutical distributor
TipRanks · 1d ago
Jyong Biotech Enters Into Non-Binding MOU With Vietnam‑Based Pharmaceutical Distribution Company To Evaluate Development And Commercialization Of MCS‑2 In Vietnam
Benzinga · 1d ago
JYONG BIOTECH EXPANDS REGIONAL PARTNERSHIPS, SIGNS MOU WITH A VIETNAM PHARMACEUTICAL DISTRIBUTOR FOR MCS‑2 MARKET ENTRY
Reuters · 1d ago
Leggett & Platt, New Fortress Energy, Bausch Health Companies And Other Big Stocks Moving Higher On Monday
Benzinga · 4d ago
Weekly Report: what happened at MENS last week (1124-1128)?
Weekly Report · 4d ago
Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story
Seeking Alpha · 11/27 12:18
Jyong Biotech signs non-binding LOI with South Korean pharma company
TipRanks · 11/24 13:45
Jyong Biotech Signs MoU With South Korean Pharmaceutical Company To Review, Evaluate Licensing, Development Of Jyong Biotech's Plant-Derived New Drug MCS-2
Benzinga · 11/24 13:35
JYONG BIOTECH LTD. SIGNS NON‑BINDING LETTER OF INTENT WITH LEADING SOUTH KOREAN PHARMACEUTICAL COMPANY TO EVALUATE IN‑LICENSING OF PLANT-DERIVED MCS DRUGS
Reuters · 11/24 13:31
Weekly Report: what happened at MENS last week (1117-1121)?
Weekly Report · 11/24 09:05
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8
TipRanks · 11/20 13:45
Jyong Biotech Completes Statistical Analysis Of Primary Efficacy Endpoints In Ongoing Phase II Clinical Trial Of MCS-8 Conducted In Taiwan
Benzinga · 11/20 13:38
JYONG BIOTECH LTD: MCS-8 REMAINS INVESTIGATIONAL NEW DRUG CANDIDATE & HAS NOT BEEN APPROVED FOR COMMERCIAL USE IN ANY JURISDICTION
Reuters · 11/20 13:30
JYONG BIOTECH ANNOUNCES COMPLETION OF PRIMARY ENDPOINT STATISTICAL ANALYSIS FOR PHASE II CLINICAL TRIAL OF MCS-8 WITH POSITIVE OUTCOMES
Reuters · 11/20 13:30
Jyong Biotech is Now Oversold (MENS)
NASDAQ · 11/19 17:04
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 11/17 17:06
Weekly Report: what happened at MENS last week (1110-1114)?
Weekly Report · 11/17 09:05
Weekly Report: what happened at MENS last week (1103-1107)?
Weekly Report · 11/10 09:05
Weekly Report: what happened at MENS last week (1027-1031)?
Weekly Report · 11/03 09:05
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 10/31 21:07
More
Webull provides a variety of real-time MENS stock news. You can receive the latest news about Jyong Biotech Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About MENS
Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.